Compare GOVX & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOVX | MBOT |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 126.9M |
| IPO Year | 1996 | 2000 |
| Metric | GOVX | MBOT |
|---|---|---|
| Price | $0.36 | $1.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 461.4K | 419.8K |
| Earning Date | 04-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,489,145.00 | $116,887.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $1.28 |
| 52 Week High | $4.40 | $3.46 |
| Indicator | GOVX | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 25.16 | 26.80 |
| Support Level | $0.16 | N/A |
| Resistance Level | $0.86 | $2.21 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 3.33 | 3.92 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.